List of Excipients in Branded Drug SURVANTA

SURVANTA Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

SURVANTA (beractant) is a natural bovine lung extract used as intratracheal replacement therapy for respiratory distress syndrome in premature infants. Its commercial and technical value is concentrated in the composition, processing, and delivery of a complex phospholipid-protein suspension rather than in conventional inactive excipients. The original patent and regulatory exclusivity periods have expired, leaving opportunities in animal-origin-free formulations, manufacturing controls, administration devices, and follow-on products.

What is SURVANTA and how is it formulated?

SURVANTA is a sterile suspension containing 25 mg of total phospholipids per mL. The active material is derived from bovine lung and includes phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins. Sodium chloride and water for injection provide the suspension vehicle. The formulation contains no antimicrobial preservative, according to the FDA prescribing information.[1]

Attribute	SURVANTA data
Active ingredient	Beractant
Product type	Natural pulmonary surfactant
Source	Bovine lung extract
Concentration	25 mg total phospholipids/mL
Route	Intratracheal
Primary indication	Respiratory distress syndrome in premature infants
Initial dose	100 mg phospholipid/kg, equal to 4 mL/kg
Dosage form	Sterile intratracheal suspension
Storage	Refrigerated at 2°C to 8°C
Preservative	None
Original NDA	NDA 019041
Manufacturer history	Ross Products, Abbott, and later AbbVie-associated commercialization

The product contains a mixture of phosphatidylcholine, phosphatidylglycerol, neutral lipids, palmitic acid, and surfactant-associated proteins. The biological performance depends on the composition and organization of the lipid film after administration. A simple excipient substitution can therefore alter spreading, adsorption, surface tension reduction, dose uniformity, or pulmonary tolerability.

What excipients are used in SURVANTA?

SURVANTA uses a minimal vehicle system. Sodium chloride provides isotonicity, while water for injection provides the liquid phase. The principal formulation challenge is the stabilization of the bovine-derived surfactant particles, not the addition of conventional solubilizers or viscosity modifiers.

Formulation components

The labeled composition includes:

• Bovine-derived phospholipids
• Surfactant-associated proteins
• Neutral lipids
• Fatty acids
• Sodium chloride
• Water for injection

The surfactant-associated proteins are functionally important. In particular, hydrophobic proteins help the lipid mixture spread across the alveolar air-liquid interface. Their presence differentiates SURVANTA from synthetic phospholipid-only products and creates substantial analytical and manufacturing requirements.

The formulation is administered as a suspension, not as a clear solution. This affects:

• Particle-size distribution
• Sedimentation behavior
• Redispersibility
• Dose uniformity
• Syringeability
• Container compatibility
• Temperature sensitivity
• Shear exposure during handling

The label instructs users to warm the vial to room temperature and gently swirl it. Vigorous shaking is avoided because mechanical stress can affect the suspension and create handling variability.[1]

What excipient strategy protects the commercial performance of SURVANTA?

The strongest protection is formulation-process integration. The composition alone is difficult to reproduce because biological performance depends on extraction, purification, lipid composition, protein content, particle structure, and filling conditions.

High-value formulation control points

Control point	Commercial relevance
Phospholipid profile	Controls film formation and surface tension reduction
Protein content and identity	Influences adsorption and dynamic activity
Lipid-to-protein ratio	Affects pulmonary spreading and stability
Particle-size distribution	Influences suspension uniformity and dose delivery
Osmolality	Affects pulmonary tolerability
pH control	Influences lipid and protein stability
Refrigerated storage	Limits hydrolysis, oxidation, and aggregation
Container closure	Protects against contamination and composition drift
Mixing and filling	Determines delivered dose uniformity
Raw-material sourcing	Creates supply and animal-origin controls

A follow-on manufacturer would need to control both release specifications and comparative functional performance. Standard chemical equivalence may not establish equivalence for a complex pulmonary surfactant. Relevant tests include surface-tension reduction, adsorption kinetics, dynamic cycling, lipid composition, protein characterization, and in-use stability.

What formulation patents protect SURVANTA?

The core composition and manufacturing patent estate for beractant originated in the development of natural and artificial pulmonary surfactants in the 1970s and 1980s. Those patents are beyond their ordinary U.S. patent terms. No commercially meaningful blocking patent protection is expected to remain for the original SURVANTA composition.

The practical barrier is regulatory and technical rather than an unexpired composition patent. A company developing a competing product would focus on:

• Non-infringing animal-origin-free compositions
• New lipid-protein ratios
• Synthetic or recombinant surfactant proteins
• Alternative stabilizing systems
• Novel unit-dose containers
• Needleless or closed administration systems
• Manufacturing processes with independent patent claims
• Combination products pairing surfactant with respiratory support

Orange Book status

SURVANTA was approved under NDA 019041. The original product’s statutory exclusivity has expired, and the product is not protected by the type of active new chemical entity exclusivity associated with a recent small-molecule launch. An up-to-date Orange Book review should distinguish between historical patents, expired listings, and any current listing associated with an approved supplemental product. The commercial opportunity is therefore based on follow-on development and product differentiation rather than preservation of originator exclusivity.[2]

When does SURVANTA lose exclusivity?

SURVANTA has already lost regulatory and patent exclusivity in the United States.

The original approval occurred in 1991. Five-year new chemical entity exclusivity, if applicable to the approval structure, would have expired in the mid-1990s. Any standard U.S. patent protection associated with the original product would also have expired by the late 2000s at the latest, depending on the patent’s filing date and any patent-term adjustment.

Exclusivity category	SURVANTA position
FDA approval	1991
NCE exclusivity	Expired
Original composition patents	Expired
Pediatric exclusivity	No current commercial effect
Orphan exclusivity	Not applicable to the core indication
Current blocking exclusivity	None expected for the original product
Biosimilar exclusivity	Not applicable as the primary pathway
Follow-on pathway	ANDA or 505(b)(2), depending on product and evidence

Are there Paragraph IV challenges to SURVANTA?

A current, commercially material Paragraph IV challenge is not central to the SURVANTA market. The product has been on the market for decades, and any original patent barriers have expired. A company seeking approval of a comparable product would face regulatory questions involving complex mixtures and locally administered pulmonary products rather than a conventional patent cliff.

An ANDA applicant would need to assess whether the FDA considers a proposed product pharmaceutically equivalent and therapeutically equivalent to the reference listed drug. If the product differs materially in source, protein content, lipid profile, concentration, or administration system, a 505(b)(2) application may be more appropriate.

The main litigation exposure would likely involve:

• New formulation patents
• Device patents
• Manufacturing-process patents
• Method-of-use patents involving dosing or rescue administration
• Trade-secret disputes concerning extraction and purification
• Supplier agreements covering bovine lung material

What method-of-use patents could affect SURVANTA competitors?

Historical use patents for surfactant replacement in premature infants are generally old. Newer method-of-use claims could target:

• Early prophylactic administration
• Rescue dosing after mechanical ventilation
• Repeat dosing schedules
• Surfactant administration through less invasive techniques
• Use during noninvasive respiratory support
• Treatment of respiratory distress outside the original neonatal population
• Combination use with inhaled nitric oxide or other respiratory interventions

A method-of-use patent would not necessarily prevent sale of the underlying surfactant for an unclaimed use. Its value would depend on physician adoption, label language, induced-infringement risk, and the ability to separate patented use from non-patented indications.

What commercial opportunities exist in SURVANTA excipients?

Animal-origin-free replacement

The strongest long-term opportunity is a synthetic or recombinant formulation that removes bovine-source materials. Potential benefits include:

• Lower animal-origin supply risk
• More consistent composition
• Easier global regulatory positioning
• Reduced pathogen and traceability concerns
• Improved manufacturing scalability
• Greater control over protein and lipid ratios

The main risk is loss of biological performance. A synthetic product must reproduce the low surface tension and rapid spreading of a natural surfactant, often with fewer components.

Synthetic peptide surfactants

Synthetic analogs of surfactant-associated proteins, particularly SP-B or SP-C mimetics, could be combined with defined phospholipids. This approach can create new composition and process patent positions. It also permits tighter control of impurity profiles and batch release.

Stabilization and shelf-life improvement

A redesigned formulation could seek:

• Greater resistance to oxidation
• Reduced lipid hydrolysis
• Improved suspension uniformity
• Longer room-temperature exposure
• Reduced sedimentation
• Lower cold-chain dependence

These opportunities are commercially relevant because neonatal intensive-care units must manage refrigerated products during urgent administration. Any stability improvement must preserve dynamic surface activity and avoid introducing excipients that impair pulmonary tolerability.

Delivery systems

Device innovation may offer a clearer path than direct excipient substitution. Opportunities include:

• Ready-to-use prefilled syringes
• Unit-dose presentations
• Closed-system catheter delivery
• Less invasive surfactant administration
• Compatibility with thin catheters and noninvasive ventilation
• Reduced handling steps
• Automated dose delivery by weight

Device patents can create differentiated products even when the underlying surfactant composition is no longer protected.

How does SURVANTA compare with competing surfactants?

Product	Active material	Approximate concentration	Main differentiation
SURVANTA	Beractant, bovine lung extract	25 mg phospholipid/mL	Natural surfactant with bovine proteins
Curosurf	Poractant alfa, porcine lung extract	80 mg phospholipid/mL	Higher concentration and lower administration volume
INFASURF	Calfactant, calf lung lavage extract	35 mg phospholipid/mL	Natural bovine-derived surfactant
Synthetic candidates	Defined lipids with synthetic or recombinant peptides	Product-specific	Animal-origin-free composition

Curosurf has a concentration and dosing-volume advantage. SURVANTA’s lower concentration requires a larger initial volume, which can influence administration logistics. Both products compete on clinical familiarity, neonatal intensive-care protocols, supply reliability, and hospital contracting.

Which companies are challenging the SURVANTA market?

Competition comes primarily from manufacturers of other pulmonary surfactants and from developers of synthetic or recombinant alternatives. The commercial field includes:

• AbbVie or its successor commercial entity for SURVANTA
• Chiesi for Curosurf
• Manufacturers associated with INFASURF
• Specialty respiratory-drug companies developing synthetic surfactants
• Device companies developing less invasive administration platforms

The market is more concentrated than a standard generic tablet market because formulation complexity, clinical evidence, hospital protocols, and neonatal administration requirements raise entry costs.

What generic launch risks exist for SURVANTA?

A generic or follow-on launch would face five principal risks:

1. Equivalence risk. Chemical similarity may not establish comparable surface activity.
2. Manufacturing risk. Natural extracts can vary by source and batch.
3. Clinical risk. Small changes in dose delivery can affect respiratory outcomes.
4. Regulatory risk. The FDA may require comparative functional and clinical evidence.
5. Commercial risk. Neonatal intensive-care units may prioritize established products and supply continuity over modest price reductions.

A successful entrant would likely need a combination of formulation equivalence, strong analytical characterization, reliable cold-chain supply, and a differentiated administration device.

What is the revenue exposure for SURVANTA?

AbbVie does not generally disclose SURVANTA as a separate material revenue line in its consolidated public reporting. Product-level revenue, market share, and margin data are therefore not reliable public metrics. The commercial value is best assessed through hospital utilization, neonatal intensive-care unit penetration, product availability, pricing, and competition from Curosurf and INFASURF rather than through a separately reported revenue figure.[3]

How strong is the SURVANTA patent estate?

The original estate is weak as a current exclusionary asset because the relevant patent and regulatory rights have expired. The defensible value lies in know-how and execution:

• Bovine lung sourcing
• Extraction and purification
• Lipid and protein specifications
• Batch consistency
• Sterile filling
• Cold-chain logistics
• Product handling instructions
• Hospital formulary relationships

A new entrant can obtain stronger protection by patenting a defined synthetic composition, a recombinant surfactant protein, an oxidation-resistant formulation, a delivery device, or a specific less-invasive administration method.

Key Takeaways

• SURVANTA is a complex bovine-derived phospholipid-protein suspension, not a conventional excipient-driven drug product.
• Sodium chloride and water for injection are the principal labeled vehicle components.
• The original patent and regulatory exclusivity periods have expired.
• Current entry barriers are technical, regulatory, manufacturing, and commercial.
• Animal-origin-free surfactants and synthetic peptide formulations offer the strongest formulation opportunities.
• Prefilled syringes, closed delivery systems, and less invasive administration may provide more practical differentiation than simple excipient substitution.
• A follow-on product may require an ANDA or 505(b)(2) strategy, depending on the degree of compositional and functional similarity.
• Curosurf and INFASURF remain the principal marketed comparators.
• Biosimilar risk is limited because SURVANTA is not primarily managed as a biologic reference product under the biosimilar pathway.
• Product-level SURVANTA revenue is not separately disclosed by AbbVie.

FAQs

Is SURVANTA a biologic or a conventional small-molecule drug?

SURVANTA is a complex biological-source pulmonary surfactant approved as a drug product. It is not a conventional small-molecule active ingredient, but its follow-on regulatory strategy is not automatically the FDA biosimilar pathway.

Can a company replace the bovine-derived components with synthetic lipids?

Yes, but the resulting product would require evidence that its surface activity, composition, safety, and clinical performance are comparable. A synthetic replacement would likely be positioned as a new or follow-on surfactant rather than as a simple excipient change.

Does SURVANTA contain preservatives?

No. The labeled formulation does not contain an antimicrobial preservative. It is supplied as a sterile single-use intratracheal suspension.[1]

What is the main manufacturing bottleneck for SURVANTA competitors?

The main bottlenecks are consistent sourcing of biological material, control of phospholipid and protein composition, sterile processing, and reproducible pulmonary surface activity.

Could a new administration device create patent protection around a SURVANTA competitor?

Yes. A device or combination-product patent could protect dose preparation, catheter delivery, closed-system administration, weight-based dosing, or delivery during noninvasive respiratory support.

References

1. U.S. Food and Drug Administration. (2023). SURVANTA (beractant) intratracheal suspension: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. American Academy of Pediatrics. (2014). Respiratory support in preterm infants at birth. Pediatrics, 133(1), 171-174.